Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPRA-CKD: Real-world adjunctive ipragliflozin for CKD prevention in type 1 diabetes
jRCT1071220115Recruiting
- Sponsor
- Ichiro Horie
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ipragliflozin in chronic kidney disease (CKD) and diabetes mellitus type 1 (T1D) (2 arms), sponsored by Ichiro Horie. Started Mar 2023; status: recruiting.
02
Drugs
ipragliflozin
03
Conditions
chronic kidney disease (CKD)diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on jRCT1071220115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071220115.